BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 27246732)

  • 21. mTOR has a developmental stage-specific role in mitochondrial fitness independent of conventional mTORC1 and mTORC2 and the kinase activity.
    Kalim KW; Zhang S; Chen X; Li Y; Yang JQ; Zheng Y; Guo F
    PLoS One; 2017; 12(8):e0183266. PubMed ID: 28813526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repression of Mammalian Target of Rapamycin Complex 1 Inhibits Intestinal Regeneration in Acute Inflammatory Bowel Disease Models.
    Guan Y; Zhang L; Li X; Zhang X; Liu S; Gao N; Li L; Gao G; Wei G; Chen Z; Zheng Y; Ma X; Siwko S; Chen JL; Liu M; Li D
    J Immunol; 2015 Jul; 195(1):339-46. PubMed ID: 26026060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
    Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
    Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mammalian target of rapamycin complex 2 signaling pathway regulates transient receptor potential cation channel 6 in podocytes.
    Ding F; Zhang X; Li X; Zhang Y; Li B; Ding J
    PLoS One; 2014; 9(11):e112972. PubMed ID: 25393730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes.
    Veilleux A; Houde VP; Bellmann K; Marette A
    Mol Endocrinol; 2010 Apr; 24(4):766-78. PubMed ID: 20203102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. mTORC1 alters the expression of glycolytic genes by regulating KPNA2 abundances.
    Chen X; Zhu Y; Wang Z; Zhu H; Pan Q; Su S; Dong Y; Li L; Zhang H; Wu L; Lou X; Liu S
    J Proteomics; 2016 Mar; 136():13-24. PubMed ID: 26844761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ceramide inhibits insulin-stimulated Akt phosphorylation through activation of Rheb/mTORC1/S6K signaling in skeletal muscle.
    Hsieh CT; Chuang JH; Yang WC; Yin Y; Lin Y
    Cell Signal; 2014 Jul; 26(7):1400-8. PubMed ID: 24650522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTORC1 inhibitors suppress meningioma growth in mouse models.
    Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-451 regulates AMPK/mTORC1 signaling and fascin1 expression in HT-29 colorectal cancer.
    Chen MB; Wei MX; Han JY; Wu XY; Li C; Wang J; Shen W; Lu PH
    Cell Signal; 2014 Jan; 26(1):102-9. PubMed ID: 23899558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Semaphorin3A regulates axon growth independently of growth cone repulsion via modulation of TrkA signaling.
    Ben-Zvi A; Ben-Gigi L; Yagil Z; Lerman O; Behar O
    Cell Signal; 2008 Mar; 20(3):467-79. PubMed ID: 18096366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia.
    Gao Y; Gao J; Li M; Zheng Y; Wang Y; Zhang H; Wang W; Chu Y; Wang X; Xu M; Cheng T; Ju Z; Yuan W
    J Hematol Oncol; 2016 Apr; 9():36. PubMed ID: 27071307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mammalian target of rapamycin controls glucose consumption and redox balance in human Sertoli cells.
    Jesus TT; Oliveira PF; Silva J; Barros A; Ferreira R; Sousa M; Cheng CY; Silva BM; Alves MG
    Fertil Steril; 2016 Mar; 105(3):825-833.e3. PubMed ID: 26698679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia/Lymphoma by Inhibiting Mammalian Target of Rapamycin.
    Watanabe T; Sato A; Kobayashi-Watanabe N; Sueoka-Aragane N; Kimura S; Sueoka E
    Anticancer Res; 2016 Jan; 36(1):95-102. PubMed ID: 26722032
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardamonin Inhibits Metastasis of Lewis Lung Carcinoma Cells by Decreasing mTOR Activity.
    Niu PG; Zhang YX; Shi DH; Liu Y; Chen YY; Deng J
    PLoS One; 2015; 10(5):e0127778. PubMed ID: 25996501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of Human Trophoblast GLUT3 Glucose Transporter by Mammalian Target of Rapamycin Signaling.
    Xu J; Lu C; Wang J; Zhang R; Qian X; Zhu H
    Int J Mol Sci; 2015 Jun; 16(6):13815-28. PubMed ID: 26086828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cancer pain relief achieved by disrupting tumor-driven semaphorin 3A signaling in mice.
    Maeda T; Yamada D; Kawahara K
    Neurosci Lett; 2016 Oct; 632():147-51. PubMed ID: 27592511
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2.
    Luo Y; Liu L; Wu Y; Singh K; Su B; Zhang N; Liu X; Shen Y; Huang S
    Oncotarget; 2015 Feb; 6(6):4286-98. PubMed ID: 25738366
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
    Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.